Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

53 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Hospitalisation patterns in interstitial lung diseases: data from the EXCITING-ILD registry.
Buschulte K, Kabitz HJ, Hagmeyer L, Hammerl P, Esselmann A, Wiederhold C, Skowasch D, Stolpe C, Joest M, Veitshans S, Höffgen M, Maqhuzu P, Schwarzkopf L, Hellmann A, Pfeifer M, Behr J, Karpavicius R, Günther A, Polke M, Höger P, Somogyi V, Lederer C, Markart P, Kreuter M. Buschulte K, et al. Among authors: hammerl p. Respir Res. 2024 Jan 4;25(1):5. doi: 10.1186/s12931-023-02588-y. Respir Res. 2024. PMID: 38178212 Free PMC article.
Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial.
Behr J, Prasse A, Kreuter M, Johow J, Rabe KF, Bonella F, Bonnet R, Grohe C, Held M, Wilkens H, Hammerl P, Koschel D, Blaas S, Wirtz H, Ficker JH, Neumeister W, Schönfeld N, Claussen M, Kneidinger N, Frankenberger M, Hummler S, Kahn N, Tello S, Freise J, Welte T, Neuser P, Günther A; RELIEF investigators. Behr J, et al. Among authors: hammerl p. Lancet Respir Med. 2021 May;9(5):476-486. doi: 10.1016/S2213-2600(20)30554-3. Epub 2021 Mar 30. Lancet Respir Med. 2021. PMID: 33798455 Clinical Trial.
Disease trajectories in interstitial lung diseases - data from the EXCITING-ILD registry.
Buschulte K, Kabitz HJ, Hagmeyer L, Hammerl P, Esselmann A, Wiederhold C, Skowasch D, Stolpe C, Joest M, Veitshans S, Höffgen M, Maqhuzu P, Schwarzkopf L, Hellmann A, Pfeifer M, Behr J, Karpavicius R, Günther A, Polke M, Höger P, Somogyi V, Lederer C, Markart P, Kreuter M. Buschulte K, et al. Among authors: hammerl p. Respir Res. 2024 Mar 6;25(1):113. doi: 10.1186/s12931-024-02731-3. Respir Res. 2024. PMID: 38448953 Free PMC article.
Ziritaxestat, a Novel Autotaxin Inhibitor, and Lung Function in Idiopathic Pulmonary Fibrosis: The ISABELA 1 and 2 Randomized Clinical Trials.
Maher TM, Ford P, Brown KK, Costabel U, Cottin V, Danoff SK, Groenveld I, Helmer E, Jenkins RG, Milner J, Molenberghs G, Penninckx B, Randall MJ, Van Den Blink B, Fieuw A, Vandenrijn C, Rocak S, Seghers I, Shao L, Taneja A, Jentsch G, Watkins TR, Wuyts WA, Kreuter M, Verbruggen N, Prasad N, Wijsenbeek MS; ISABELA 1 and 2 Investigators. Maher TM, et al. JAMA. 2023 May 9;329(18):1567-1578. doi: 10.1001/jama.2023.5355. JAMA. 2023. PMID: 37159034 Free PMC article.
Endobronchial Coil System versus Standard-of-Care Medical Management in the Treatment of Subjects with Severe Emphysema.
Klooster K, Valipour A, Marquette CH, Boutros J, Mal H, Marceau A, Shah PL, Conway F, Deslée G, Bourdin A, Pison C, Grah C, Hetzel M, Schumann C, Kessler R, Huebner RH, Skowasch D, Darwiche K, Hammerl P, Stanzel F, Bezzi M, Dutau H, Herth FJF, Slebos DJ. Klooster K, et al. Among authors: hammerl p. Respiration. 2021;100(8):804-810. doi: 10.1159/000515744. Epub 2021 May 7. Respiration. 2021. PMID: 33965944 Free PMC article. Clinical Trial.
IL-31 transgenic mice show reduced allergen-induced lung inflammation.
Neuper T, Neureiter D, Sarajlic M, Strandt H, Bauer R, Schwarz H, Suchanek P, Korotchenko E, Dillon SR, Hammerl P, Stoecklinger A, Weiss R, Horejs-Hoeck J. Neuper T, et al. Among authors: hammerl p. Eur J Immunol. 2021 Jan;51(1):191-196. doi: 10.1002/eji.202048547. Epub 2020 Jul 21. Eur J Immunol. 2021. PMID: 32648940 Free PMC article.
The cytoskeletal regulator HEM1 governs B cell development and prevents autoimmunity.
Salzer E, Zoghi S, Kiss MG, Kage F, Rashkova C, Stahnke S, Haimel M, Platzer R, Caldera M, Ardy RC, Hoeger B, Block J, Medgyesi D, Sin C, Shahkarami S, Kain R, Ziaee V, Hammerl P, Bock C, Menche J, Dupré L, Huppa JB, Sixt M, Lomakin A, Rottner K, Binder CJ, Stradal TEB, Rezaei N, Boztug K. Salzer E, et al. Among authors: hammerl p. Sci Immunol. 2020 Jul 10;5(49):eabc3979. doi: 10.1126/sciimmunol.abc3979. Sci Immunol. 2020. PMID: 32646852 Free PMC article.
Epidermal activation of Hedgehog signaling establishes an immunosuppressive microenvironment in basal cell carcinoma by modulating skin immunity.
Grund-Gröschke S, Ortner D, Szenes-Nagy AB, Zaborsky N, Weiss R, Neureiter D, Wipplinger M, Risch A, Hammerl P, Greil R, Sibilia M, Gratz IK, Stoitzner P, Aberger F. Grund-Gröschke S, et al. Among authors: hammerl p. Mol Oncol. 2020 Sep;14(9):1930-1946. doi: 10.1002/1878-0261.12758. Epub 2020 Jul 21. Mol Oncol. 2020. PMID: 32615027 Free PMC article.
Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD.
Rabe KF, Martinez FJ, Ferguson GT, Wang C, Singh D, Wedzicha JA, Trivedi R, St Rose E, Ballal S, McLaren J, Darken P, Aurivillius M, Reisner C, Dorinsky P; ETHOS Investigators. Rabe KF, et al. N Engl J Med. 2020 Jul 2;383(1):35-48. doi: 10.1056/NEJMoa1916046. Epub 2020 Jun 24. N Engl J Med. 2020. PMID: 32579807 Clinical Trial.
53 results